Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02312206 · ClinicalTrials.gov registry record · Phase 3
The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis
A Phase 3 study, sponsored by Prothena Biosciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 260
- Enrollment target
NCT02312206 is a Phase 3 study that was terminated before completion, run by Prothena Biosciences. The registered enrollment target is 260 participants.
The verdict
NCT02312206, a Phase 3 study, was terminated before completion, sponsored by Prothena Biosciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 260 participants
- Enrollment target
Study Summary
This is a multi-center, international, randomized, double-blind, placebo-controlled, two-arm efficacy and safety study in subjects newly diagnosed with AL amyloidosis. Subjects will remain on-study until study completion, which will occur when all primary endpoint events (all-cause mortality or cardiac hospitalizations) have been reached.
Interventions
- OTHER Placebo
- DRUG NEOD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2015-02 |
| Est. Completion | 2018-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02312206
The ClinicalTrials.gov registry entry for NCT02312206 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prothena Biosciences, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02312206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02312206 about?
NCT02312206 is a clinical study titled "The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis". This is a multi-center, international, randomized, double-blind, placebo-controlled, two-arm efficacy and safety study in subjects newly diagnosed with AL amyloidosis. Subjects will remain on-study until study completion, which will occur when all primary endpoint events (all-cause mortality or card...
What is the current status of trial NCT02312206?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 260 participants. The study started on 2015-02. Estimated completion is 2018-05.
What interventions are being tested in trial NCT02312206?
The interventions under investigation include: Placebo (OTHER), NEOD001 (DRUG).
Who is sponsoring clinical trial NCT02312206?
This trial is sponsored by Prothena Biosciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.